CURED Co., Ltd. announced that it expects to receive ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd.
February 26, 2019
Share
CURED Co., Ltd announced that it will issue 88,000 common shares at ¥6,800 per share for gross proceeds of ¥598,400,000 on February 27, 2019. The transaction will include participation from existing investor Immuno-Biological Laboratories Co., Ltd. Post the closing, the investor stake will increase from 5.67% to 23.79% and the number of shares held will increase from 21,000 to 109,000 in the company. The shares will be issued through a third party allotment method. The transaction is expected to close on March 29, 2019. The transaction has been approved by the board of directors of the investor.
Immuno-Biological Laboratories Co., Ltd. is a Japan-based company engaged in the research, development, manufacture and sales of pharmaceutical products and quasi-drugs. The Company operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.